Clinical characteristics and antimicrobial susceptibility of Fusobacterium species isolated over 10 years at a Japanese university hospital.

Antibiotic susceptibility Fusobacterium Minimum inhibitory concentration Solid organ malignancy

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
19 Dec 2023
Historique:
received: 16 10 2023
accepted: 02 12 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 19 12 2023
Statut: aheadofprint

Résumé

Anaerobic bacteria, existing on human skin and mucous membranes, can cause severe infections with complications or mortality. We examined the clinical characteristics of patients infected with Fusobacterium spp. and assessed their antibiotic susceptibility. Clinical data were collated from patients diagnosed with Fusobacterium infections in a Japanese university hospital between 2014 and 2023. Antibiotic susceptibility tests were conducted following the Clinical and Laboratory Standards Institute guidelines. We identified 299 Fusobacterium isolates. The median age was 61 years (range, 14-95 years), with females constituting 43.1% of the patients. Most infections were community-acquired (84.6%, 253/299). Multiple bacterial strains were isolated simultaneously in 74.6% of cases. One-fourth of the patients had solid organ malignancies (25.4%, 76/299), and 14.5% (11/76) of those had colorectal cancer. The 30-day mortality rate was 1.3%. Fusobacterium species were isolated from blood cultures in 6% (18/299) of the patients. Patients, aged 75 years or older, with cerebrovascular disease or hematologic malignancy exhibited significantly higher prevalence of blood culture isolates in univariate analysis. Each Fusobacterium species had its characteristic infection site. Approximately 5% F. nucleatum and F. necrophorum isolates showed penicillin G resistance. Moxifloxacin resistance was observed in varying degrees across strains, ranging from 4.6 to 100% of isolates. All isolates were sensitive to β-lactam/β-lactamase inhibitors, carbapenems, and metronidazole. We show a link between Fusobacterium species and solid organ malignancies. We observed resistance to penicillin, cefmetazole, clindamycin, and moxifloxacin, warranting caution in their clinical use. This study offers valuable insights for managing Fusobacterium infections and guiding empirical treatments.

Identifiants

pubmed: 38112966
doi: 10.1007/s10096-023-04734-2
pii: 10.1007/s10096-023-04734-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Centor RM, Atkinson TP, Xiao L (2022) Fusobacterium necrophorum oral infections - a need for guidance. Anaerobe 75:102532. https://doi.org/10.1016/j.anaerobe.2022.102532
doi: 10.1016/j.anaerobe.2022.102532 pubmed: 35122953
Chen Y, Huang Z, Tang Z, Huang Y, Huang M, Liu H, Ziebolz D, Schmalz G, Jia B, Zhao J (2022) More than just a periodontal pathogen -the research progress on Fusobacterium nucleatum. Front Cell Infect Microbiol 12:815318. https://doi.org/10.3389/fcimb.2022.815318
doi: 10.3389/fcimb.2022.815318 pubmed: 35186795 pmcid: 8851061
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22:299–306. https://doi.org/10.1101/gr.126516.111
doi: 10.1101/gr.126516.111 pubmed: 22009989 pmcid: 3266037
Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE (2001) Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 45:1238–1243. https://doi.org/10.1128/AAC.45.4.1238-1243.2001
doi: 10.1128/AAC.45.4.1238-1243.2001 pubmed: 11257040 pmcid: 90449
Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT (2002) High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother 46:2908–2913. https://doi.org/10.1128/AAC.46.9.2908-2913.2002
doi: 10.1128/AAC.46.9.2908-2913.2002 pubmed: 12183246 pmcid: 127412
Kim M, Yun SY, Lee Y, Lee H, Yong D, Lee K (2022) Clinical differences in patients infected with Fusobacterium and antimicrobial susceptibility of Fusobacterium isolates recovered at a tertiary-care hospital in Korea. Ann Lab Med 42:188–195. https://doi.org/10.3343/alm.2022.42.2.188
doi: 10.3343/alm.2022.42.2.188 pubmed: 34635612 pmcid: 8548237
Kajihara T, Yahara K, Kitamura N, Hirabayashi A, Hosaka Y, Sugai M (2023) Distribution, trends, and antimicrobial susceptibility of Bacteroides, Clostridium, Fusobacterium, and Prevotella species causing bacteremia in Japan during 2011–2020: a retrospective observational study based on national surveillance data. Open Forum Infect Dis 10:ofad334. https://doi.org/10.1093/ofid/ofad334
doi: 10.1093/ofid/ofad334 pubmed: 37469615 pmcid: 10352651
CLSI (2023) CLSI M100-ED33:2023 Performance standards for antimicrobial susceptibility testing, 33rd ed. Clinical and Laboratory Standards Institute. em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED33:2023&scope=user. Accessed 18 September 2023
Kwong TNY, Wang X, Nakatsu G, Chow TC, Tipoe T, Dai RZW, Tsoi KKK, Wong MCS, Tse G, Chan MTV, Chan FKL, Ng SC, Wu JCY, Wu WKK, Yu J, Sung JJY, Wong SH (2018) Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology 155:383-390.e8. https://doi.org/10.1053/j.gastro.2018.04.028
doi: 10.1053/j.gastro.2018.04.028 pubmed: 29729257
Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, Imanaga D, Sakai K, Matsumoto T, Nishioka M, Takami T, Suzuki N, Hazama S, Nagano H, Sakaida I, Yamasaki T (2018) Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol 53:517–524. https://doi.org/10.1007/s00535-017-1382-6
doi: 10.1007/s00535-017-1382-6 pubmed: 28823057
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14:195–206. https://doi.org/10.1016/j.chom.2013.07.012
doi: 10.1016/j.chom.2013.07.012 pubmed: 23954158 pmcid: 3770529
Lee SJ, Baek YJ, Kim JN, Lee KH, Lee EH, Yeom JS, Choi JY, Ku NS, Ahn JY, Kim JH, Jeong SJ (2022) Increasing Fusobacterium infections with Fusobacterium varium, an emerging pathogen. PLoS One 17:e0266610. https://doi.org/10.1371/journal.pone.0266610
doi: 10.1371/journal.pone.0266610 pubmed: 35421136 pmcid: 9009667
Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N (2003) Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52:79–83. https://doi.org/10.1136/gut.52.1.79
doi: 10.1136/gut.52.1.79 pubmed: 12477765 pmcid: 1773498
Vidaurrazaga MM, McKinley GF, Camins BC (2020) Postpartum Fusobacterium gonidiaformans bacteremia. Anaerobe 62:102168. https://doi.org/10.1016/j.anaerobe.2020.102168
doi: 10.1016/j.anaerobe.2020.102168 pubmed: 32045837
Tena D, Losa C, Medina-Pascual MJ, Sáez-Nieto JA (2014) Fournier’s gangrene caused by Actinomyces funkei, Fusobacterium gonidiaformans and Clostridium hathewayi. Anaerobe 27:14–16. https://doi.org/10.1016/j.anaerobe.2014.02.004
doi: 10.1016/j.anaerobe.2014.02.004 pubmed: 24631671
Stavreas NP, Amanatidou CD, Hatzimanolis EG, Legakis I, Naoum G, Lakka-Papadodima E, Georgoulias G, Morfou P, Tsiodras S (2005) Thyroid abscess due to a mixed anaerobic infection with Fusobacterium mortiferum. J Clin Microbiol 43:6202–6204. https://doi.org/10.1128/JCM.43.12.6202-6204.2005
doi: 10.1128/JCM.43.12.6202-6204.2005 pubmed: 16333131 pmcid: 1317160
Matsukawa Y, Kitamura N, Kaneko M, Yoshioka D, Miki T, Nishinarita S, Horie T, Hosokawa N, Iwasaki Y, Kumasaka K, Kawano K (2003) Multibacterial sepsis in an alcohol abuser with hepatic cirrhosis. Intern Med 42:208–210. https://doi.org/10.2169/internalmedicine.42.208
doi: 10.2169/internalmedicine.42.208 pubmed: 12636245
Ullrich E, Grisold AJ, Feierl G, Lumenta DB, Leitner E (2016) Severe forefoot infection complicated by Fusobacterium russii. Anaerobe 42:162–165. https://doi.org/10.1016/j.anaerobe.2016.10.010
doi: 10.1016/j.anaerobe.2016.10.010 pubmed: 27789247
Schuetz AN (2014) Antimicrobial resistance and susceptibility testing of anaerobic bacteria. Clin Infect Dis 59:698–705. https://doi.org/10.1093/cid/ciu395
doi: 10.1093/cid/ciu395 pubmed: 24867792
Könönen E, Conrads G, Nagy E (2015) Bacteroides, Porphyromonas, Prevotella, Fusobacterium, and other anaerobic gram-negative rods. Manual of clinical microbiology. ASM Press, Washington, DC, pp 967–993
Reissier S, Penven M, Guérin F, Cattoir V (2023) Recent trends in antimicrobial resistance among anaerobic clinical isolates. Microorganisms 11:1474. https://doi.org/10.3390/microorganisms11061474
doi: 10.3390/microorganisms11061474 pubmed: 37374976 pmcid: 10302625

Auteurs

Nobuaki Mori (N)

Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.
Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Akiko Nakamura (A)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Jun Hirai (J)

Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.
Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Nobuhiro Asai (N)

Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.
Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Yuichi Shibata (Y)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Mina Takayama (M)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Yuzuka Kawamoto (Y)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Narimi Miyazaki (N)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Daisuke Sakanashi (D)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Tomoko Ohno (T)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Atsuko Yamada (A)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Hiroyuki Suematsu (H)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Isao Koita (I)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Sumie Chida (S)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Toshiaki Ohta (T)

Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.

Hiroshige Mikamo (H)

Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan. mikamo@aichi-med-u.ac.jp.
Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan. mikamo@aichi-med-u.ac.jp.

Classifications MeSH